SVB Securities analyst Mani Foroohar maintained a Hold rating on Ionis Pharmaceuticals (IONS - Research Report) on November 14. The company's shares closed yesterday at $43.52.Foroohar covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and Ionis Pharmaceuticals. According to TipRanks, Foroohar has an average return of -12.7% and a 44.13% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals with a $53.78 average price target, representing a 23.58% upside. In a report released on November 10, Barclays also maintained a Hold rating on the stock with a $44.00 price target.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-their-hold-rating-for-ionis-pharmaceuticals-ions-2?utm_source=advfn.com&utm_medium=referral
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more Ionis Pharmaceuticals Charts.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more Ionis Pharmaceuticals Charts.